Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care.

Germantown, Maryland Monday, February 10, 2025, 16:00 Hrs [IST] ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor ...

Lynn Nazareth does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Senseonics Holdings (NYSEAMERICAN:SENS) makes implantable continuous glucose monitoring (CGM) systems that help people with diabetes track their blood sugar in real time. It offers the Eversense line ...

Senseonics Holdings (NYSEAMERICAN:SENS) makes implantable continuous glucose monitoring (CGM) systems that help people with diabetes track their blood sugar in real time. It offers the Eversense ...